Modified HIL-6
作者： Hideo Inoue , Makoto Kakitani , Toshifumi Mikayama , Toshihiko Kadoya
DOI:
关键词:
摘要: Disclosed are PEG-modified "interleukin-6" derivatives (PEG-IL-6) having an extended plasma half-life, as well enhanced in vivo IL-6 biological activities. Methods for producing the modified glycosylated and unglycosylated proteins or polypeptides, as, their use treating hematopoietic disorders difficiencies, particularly acute thrombocytopenia, also disclosed. The PEG is example form of formula: (see formula 1) (wherein n m each integer 7 to 600, R1 R2 lower alkyl).
google.co.za 参考文章(16)
Dana M. Fowlkes, Charles T. Tackney, Synthetic interleukin-6 ,(1989)
Yasushi Nakagawa, Takashi Ito, Chemically modified protein with polyethyleneglycol ,(1987)
Walter J. Laird, Lois Aldwin, Danute E. Nitecki, Paula J. Shadle, Margaret Moreland, John D. Young, Nandini Katre, Kirston E. Koths, Conjugation of polymer to colony stimulating factor-1 ,(1989)
Frank F. Davis, Theodorus Van Es, Nicholas C. Palczuk, Non-immunogenic polypeptides ,(1977)
Kouichi Miyata, Masahira Nakamura, Yasushi Nakagawa, Modified enzymes, production and use thereof ,(1986)
Makoto Morimoto, Masami Okabe, Motoo Yamasaki, Yoshiharu Yokoo, Modified human G-CSF ,(1989)
Lawrence M. Thousand Oaks Souza, Production of pluripotent granulocyte colony-stimulating factor. ,(1986)
James William Thomson, Nandini Katre, Michael James Knauf, Tumor necrosis factor formulation and its preparation ,(1987)
Michael James Knauf, Nandini Katre, Solubilization of proteins for pharmaceutical compositions using polymer conjugation ,(1986)